Keywords: Corcept Thera, Korlym royalties

Corcept sells capped royalty on future sales for $30 million

Article | 09 August 2012

Print This

US drug developer Corcept Therapeutics (Nasdaq: CORT) announced that it has sold to an investment fund managed by Pharmakon Advisors ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in